Literature DB >> 2985641

Abnormal expression pattern of Tac and T9 antigens on in vitro activation of leukemic T cells.

H Tsuda, K Takatsuki.   

Abstract

Mitogen-induced T-lymphocyte proliferation is dependent on the presence of both interleukin 2 (IL-2) and transferrin, even though resting lymphocytes do not have receptors for either. Recently, it has been reported that IL-2 stimulates T-lymphocyte proliferation via IL-2 receptor by induction of transferrin receptor on these cells. Using leukemic T cells as a model of the monoclonal mature T cell, we examined those sequential steps of T-cell activation. Our studies revealed that transferrin receptors do not always appear after IL-2 receptor expression, IL-2 up-regulates the expression of IL-2 receptor but not of transferrin receptor, and IL-2 can initiate DNA synthesis without altering transferrin receptor expression. Thus, the sequential activation steps reported for normal T cells were not observed in the present study on leukemic T cells. These data suggest that there are other pathways to DNA synthesis in leukemic T cells and even in normal T cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985641     DOI: 10.1007/bf00915008

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

1.  The role of iron and transferrin in lymphocyte transformation.

Authors:  J H Brock; T Mainou-Fowler
Journal:  Immunol Today       Date:  1983-12

2.  Adult T-cell leukemia cells expressing OKT 17 antigen in the activated state.

Authors:  H Tsuda; K Takatsuki
Journal:  Hematol Oncol       Date:  1983 Jul-Sep       Impact factor: 5.271

3.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  Regulation of transferrin receptor expression in concanavalin A stimulated and Gross virus transformed rat lymphoblasts.

Authors:  T A Hamilton
Journal:  J Cell Physiol       Date:  1982-10       Impact factor: 6.384

5.  Correlation of aberrant proliferation with T-cell growth factor in adult T-cell leukemia cells.

Authors:  H Tsuda; K Takatsuki
Journal:  Hematol Oncol       Date:  1983 Apr-Jun       Impact factor: 5.271

6.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

7.  Evidence for an interleukin-independent pathway for human lymphocyte activation.

Authors:  G A Koretzky; R P Daniele; W C Greene; P C Nowell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

8.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

9.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

10.  Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor.

Authors:  J E Gootenberg; F W Ruscetti; J W Mier; A Gazdar; R C Gallo
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  1 in total

1.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.